Ardelyx reports FY2022 net loss $67.2M; IBSRELA sales $15.6M; XPHOZAH NDA resubmission expected early Q2 2023

ARDELYX, INC.

Net loss for FY2022 was $67.2M ($0.42/share) vs $158.2M ($1.52/share) in 2021.
IBSRELA net product sales $15.6M for FY2022, with $8.7M in Q4; consistent prescription growth.
Cash and investments $123.9M at Dec 31, 2022; $121.0M at Feb 28, 2023 (includes $20M ATM proceeds).
XPHOZAH NDA resubmission on track for early Q2 2023 after productive FDA Type A meeting.
Debt facility amended: interest-only period may extend to Mar 2025; additional $22.5M available contingent on FDA approval and revenue targets.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ARDELYX, INC. reported financial results for fourth quarter and full year ended December 31, 2022.

Period: fourth quarter and full year ended December 31, 2022
Result: reported results

Exact text from the filing

Ardelyx Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Continued successful launch of IBSRELA, ending FY 2022 with $15.6 million in net product sales

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ARDELYX, INC. reported financial results for fourth quarter and full year ended December 31, 2022.

Period: fourth quarter and full year ended December 31, 2022
Result: reported results

Exact text from the filing

Full Year 2022 Financial Results • Cash Position: As of December 31, 2022, the company had total cash, cash equivalents and short-term investments of $123.9 million, as compared to total cash, cash equivalents and short-term investments of $116.7 million as of December 31, 2021.

View on SEC.gov

Browse all earnings releases →

ARDELYX, INC. filing history →

Source: SEC EDGAR

accession 0001628280-23-006039

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.